Structure Therapeutics (GPCR) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Zymeworks (ZYME) has outperformed Structure Therapeutics (GPCR) over the past year, gaining 60.8% versus a loss of 6.1%. Zymeworks is the larger company by market cap ($1.90 billion vs $1.90 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | ZYME |
|---|---|---|
| Share price | $26.68 | $26.53 |
| Market cap | $1.90B | $1.90B |
| 1-day change | -2.88% | +3.43% |
| YTD return | -61.64% | +0.76% |
| 1-year return | -6.12% | +60.79% |
| 5-year return | — | +2.27% |
| Forward P/E | — | 30.43 |
| EPS (TTM) | $-3.03 | $-2.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $94.90 | $31.34 |
| 52-week low | $25.59 | $16.00 |
| Distance from 52-week high | -71.89% | -15.35% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +296.48% | +55.33% |
| Average volume | 956.06K | 673.06K |
| Shares outstanding | 71.31M | 71.20M |
| Employees | 281 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYME has outperformed GPCR by 66.9 percentage points over the past year.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
GPCR vs ZYME FAQ
Which is bigger, Structure Therapeutics or Zymeworks?
Zymeworks (ZYME) is larger, with a market capitalization of $1.90B compared with $1.90B for Structure Therapeutics (GPCR).
Which stock has performed better over the past year, GPCR or ZYME?
ZYME returned +60.79% over the past 12 months, compared with -6.12% for GPCR (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.